Company news
Ensysce Biosciences, Inc. news in 2023
Ensysce Biosciences, Inc.'s news releases, calls and decks from 2023, newest first.
Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023
December 18, 2023
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic
December 13, 2023
Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing
November 28, 2023
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States
November 27, 2023
Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study
November 15, 2023
Ensysce Biosciences Reports Third Quarter 2023 Financial Results
November 8, 2023
Ensysce Biosciences Secures $1.7 Million Convertible Note Financing
October 23, 2023
Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360
October 17, 2023
Ensysce Biosciences Releases "Highlights Video" of PAINWeek 2023 Symposium
October 12, 2023
Ensysce Biosciences to Chair the Fierce New Product Planning Summit 2023
October 2, 2023
Ensysce Biosciences Announces Completion of Site Initiation Visit for PF614-201 Clinical Study
September 25, 2023
Ensysce Biosciences to Host Research and Development FAQ Session Following PAINWeek Symposium on September 21, 2023
September 18, 2023
Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies
September 13, 2023
Ensysce Presents "A New Generation of Safer Pain Treatments"
September 6, 2023
Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 4, 2023
Ensysce Biosciences to Present Clinical Dataset at Major PAINWeek Scientific Symposium
August 13, 2023
Ensysce Biosciences Reports Second Quarter 2023 Financial Results
August 10, 2023
Ensysce Biosciences Announces IRB Approval of Key Study Protocol
August 7, 2023
Ensysce Biosciences Announces Engagement of Alacrita Consulting
July 25, 2023
Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo
June 26, 2023
Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website
June 6, 2023
Ensysce Biosciences Reports First Quarter 2023 Financial Results
May 14, 2023
Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering
May 11, 2023
Ensysce Biosciences, Inc. Announces Pricing of $7 Million Public Offering
May 9, 2023
Ensysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose Protection
May 8, 2023
Ensysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614
April 2, 2023
Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
March 29, 2023
Ensysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection Study
March 21, 2023
Ensysce Biosciences Announces Critical Step in Human Abuse Potential Study of PF614 With Database Lock
February 27, 2023
Ensysce Biosciences Provides Corporate Update
February 22, 2023
Ensysce Biosciences to Present its Overdose Protection Program at the 4th Annual NIH 'HELPING END ADDICTION LONG-TERM' (HEAL) Meeting
February 13, 2023
Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules
February 6, 2023
Ensysce Biosciences, Inc. Announces $3 Million Registered Direct Offering
February 2, 2023
Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock
January 31, 2023
Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study
January 24, 2023
Ensysce Biosciences Issues 2023 Shareholder Letter
January 10, 2023
Ensysce Biosciences Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential Trial
January 3, 2023
Calls in 2023
Decks in 2023
- Investor Presentation (January 2023)
Investor deck · 38 slides · Jan 19, 2023